Professional Research
David M. Dick, MD, FACC

Principal Investigator

• Trimedyne Excimer Laser study to evaluate safety and efficacy in occlusive coronary disease.

Sub-Investigator

• EPIC 7E3 - A Study of Chimeric 7E3 Fab in Patients Undergoing High Risk Coronary Angioplasty
• IMPACT I - A Randomized, Double-blind Trial of Integrelin vs Placebo in the Setting of Coronary Angioplasty
• IMPACT II - A Randomized, Double-bind, Efficacy and Safety Evaluation of Two Dosing Regimens of Integrelin vs Placebo for Reducing the Complication of Coronary Angioplasty
• CARS (Coumadin Aspirin Re-infarction Study): A Randomized, Double-blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Re-infarction, Cardiovascular Death, and Stroke in Post Myocardial Infarction Patients
• LEXUS with Gas (Losartan Exercise in the United States with Gas Exchange Analysis) - A Multi-center, Double-blind, Randomized, Parallel, Placebo-controlled Study to Investigate the Effects of Losartan on the Exercise Capacity and Clinical Status of Patients with Symptomatic Heart Failure
• TIMI 10A - A Phase I, Dose-escalation, Single Administration Study to Determine the Pharmacokinetics, Safety, and Tolerance of TNK-tPA in Acute Myocardial Infarction
• PRAISE (Prospective Randomized Amlodipine Survival Evaluation) - A Randomized, Double-blind, Dose-titration, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Amlodipine on Mortality and Morbidity in Patients with Severe Heart Failure
• TIMI 10B - A Phase II Randomized, Open-label, Multi-center, International Trial of the Patency of TNIK-tPA in Acute Myocardial Infarction
• CARDIZEM CD - The Safety and Efficacy of Cardizem CD for the Treatment of Stable Angina Pectoris
• DUCCS 1 (Duke University Clinical Cardiology Study) - A Randomized Trial of Heparin in Conjunction with Anistreplase in Acute Myocardial Infarction
• DUCCS 2 (Duke University Clinical Cardiology Study) - A Randomized Trial of rt-PA (Activase) with Heparin vs APSAC (Eminase) Without Heparin in Acute Myocardial Infarction
• HIRULOG - A Comparative Study for the Safety and Efficacy of B68967 with Heparin in Patients with Unstable Angina Undergoing PTCA
• FIRST - A Multi-national, Open, Randomized, Parallel Group Comparison of the Effects of Chronic FLOLAN Therapy Plus Conventional Therapy to Conventional Therapy Alone on Survival in Patients with Severe Refractory Congestive Heart Failure
• LATE (Late Assessment of Thrombolytic Therapy) - An Anglo-Scandinavian North American Multi-center Trial of Alteplase Therapy in Patients Who Present with Acute Myocardial Infarction Greater Than 12 Hours Following Onset of Symptoms
• TIMI 3 (Thrombolysis In Myocardial Infarction) - The Comprehensive Management of Unstable Angina and Non-Q Wave Infarction in a Randomized, Double-blind Fashion with tPA or Placebo
• CAVEAT 2 - Coronary Angioplasty versus Excisional Arthectomy Trial in Saphenous Vein Grafts
• Integrelin versus Aspirin in Unstable Angina - A Randomized, Double-blind Comparative Safety and Efficacy Evaluation (Phase II) of Integrelin vs Aspirin in the Management of Unstable Angina.
• UTOPIA - Adjunctive Tissue Plasminogen Activator and Heparin During Angioplasty in Unstable Angina
• EPILOG - A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating 30 Day and 6 Month Clinical Outcome Following Percutaneous Coronary Intervention in Patients Treated with c7E3 Fab Bolus Plus 12 Hour Infusion Given with Either Standard-dose Adjusted and Low-weight adjusted Heparin
• GUSTO III (The Global Use of Strategies to Open Occluded Coronary Arteries) - A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction
• PURSUIT - A Randomized, Double-blind Evaluation of the Efficacy and Safety of Two Dosing Regimens of Integrelin versus Placebo for Reducing Mortality and Myocardial Re-infarction in Patients with Unstable Angina or Non Q-Wave Myocardial Infarction
• The Use of Phentermine and Fenfluramine in Obese Patients with Established Cardiovascular Disease
• SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) - A Randomized, Double-blind, Placebo-controlled Trial of Sertraline (Zoloft) for Major Depression After Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina
• Val-HeFT - A Multicountry, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Assess the Effect of Valsartan on Morbidity and Mortality, Signs and Symptoms, and Quality of Life in Patients with Stable, Chronic Congestive Heart Failure
• ATLAST - Antiplatelet Therapy vs Lovenox Plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis
• GUARDIAN - A Double-blind Trial to Investigate Whether Cariporide Reduces the Combined Incidence of All-cause Mortality and Myocardial Infarction in Patients at Risk of Myocardial Necrosis Due to ACS Related to the Disease Process or to an Interventional Cardiac Procedure
• SPEED (Strategies for Patency Enhancement in the Emeergency Department) - A Phase II, Randomized, Open-label, Angiographic Trial Evaluating the Benefit of ReoPro Bolus Plus 12 Hour Infusion With and Without Thrombolytic Therapy for Acute Myocardial Infarction
• PARAGON B - A Randomized, Double-blind, Placebo-Controlled Study of Lamifiban (Ro 44-9883) in Patients with Unstable Angina/Non-Q Wave Myocardial Infarction
• Dofetilide 128 - A Randomized, Double-blind, Parallel, Placebo-controlled Evaluation of Orally Administered Dofetilide in Patients with Symptomatic Paroxysmal Atrial Fibrillation or Flutter
• PRAISE 2 (Prospective Randomized Amlodipine Survival Evaluation 2) - A Randomized, Placebo-controlled Trial to Evaluate the Effect of Amlodipine on Mortality in Patients with Severe Non-Ischemic Cardiomyopathy
• Dofetilide 128A Extension - A Long-term Extension Double-blind Converting to Open-label
• SPICE (Study of Patients Intolerant of Converting Enzymes) - A Pilot Phase II Trial and Registry of Patients with Class II-IV Heart Failure and Left Ventricular Dysfunction
• APLAUD - A 12 Week, Double-blind, Parallel-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Platelet Aggregation of a Dose Range of SB 214857 When Added to Aspirin in Patients with Myocardial Infarction, Unstable Angina, Transient Ischemic Attack, or Stroke
• ELITE II - A Multi-center, Double-blind, Randomized, Parallel, Captopril-Controlled Study to Evaluate the Effects of Losartan on Mortality in Patients with Symptomatic Heart Failure
• WIZARD - A Randomized, Double-blind, Placebo-controlled Trial of the Effect of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae
• CAPRICORN - A Multi-national, Multi-center, Randomized, Double-blind, Parallel Group Study to Determine the Effects of Carvedilol on Mortality in Patients with Left Ventricular Dysfunction, With or Without Clinical Evidence of Heart Failure, Post Myocardial Infarction
• HALT MI - A Phase 2 Safety and Efficacy Study of Hu23F2G on Patients with Acute Myocardial Infarction with Direct Angioplasty
• ASTRA - A Double-blind, Placebo-controlled, Multi-center Pilot Study to Assess the Safety and ex vivo Platelet Aggregation Response of Intravenous AR-C69931MX in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty, With or Without Intracoronary Stent Placement
• ASTRA (Part 2 Open-label vs Abciximab) - A Muti-center Pilot Study to Assess the Safety and ex vivo Platelet Aggregation Response of Intravenous AR-C69931MX in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty With or Without Stent Placement
• INTRO AMI - A Pilot Phase II Safety and Efficacy Evaluation of Eptifbatide (Integrelin) in Patients Receiving Low Dose and Standard Dose Thrombolytic Therapy (Alteplase) for Acute Myocardial Infarction (AMI)
• LIMIT AMI - A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Angiographic Trial of the Safety and Efficacy of rhuMAb CD18 in Acute Myocardial Infarction
• GUSTO IV ACS - A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of ReoPro™, Given as a Bolus Followed by a 24 or 48 Hour Infusion, for the Treatment of Acute Coronary Syndrome Without ST Segment Elevation
• GUSTO IV AMI - A Phase III, Randomized, Open-label Trial Evaluating the Efficacy and Safety of ReoPro®(Abciximab) in Combination with Reduced Dose Retavase®/Rapilysin™Recombinant Plasminogen Activator, Retaplase, r-PA) for the Treatment of Acute Myocardial Infarction